World’s First Trifocal Intraocular Lens, world record in Waltham, Massachusetts

October 19, 2025

Waltham, Massachusetts, United States--BVI Medical has gained US Food and Drugs Administration (FDA) approval for FineVision HP, in an effort to expand coverage in the multifocal intraocular lens market; the FineVision HP us the world’s first trifocal intraocular lens (IOL) for cataract surgery, according to the WORLD RECORD ACADEMY.

"“FDA approval in the U.S. means even more patients will benefit from this breakthrough technology.” FINEVISION HP was a breakthrough diffractive design creating the world's first trifocal IOL, establishing an entirely new standard in cataract surgery. Exceptional reliability," the official website says.

"The pioneering work of Christophe Pagnoulle, BVI R&D director, and ophthalmologist Damien Gatinel, M.D., Ph.D., brought the FINEVISION HP to market and heralded a new era of premium IOLs.

"FINEVISION HP stands as the world’s first trifocal IOL and remains the global benchmark in trifocal innovation with a legacy of more than 15 years of clinical success and millions of implantations worldwide. U.S. surgeons and patients now gain access to this transformative lens, recognized globally for its patented diffractive optic design delivering balanced vision at far, intermediate and near distances."

“FINEVISION HP redefined premium cataract surgery and continues to set the gold standard in premium IOL innovation,” said Shervin Korangy, president and CEO of BVI. “This FDA approval marks a pivotal step in expanding our IOL portfolio in the United States, supporting our mission to deliver best-in-class visual outcomes for patients globally," the official website says.

"The third-generation FINEVISION HP incorporates BVI’s proprietary POD platform and CoPODize™ technology, harmonizing light distribution and minimizing visual disturbances. Its unique double C-loop, four-point haptic design supports long-term stability and precise centration in the capsular bag.

“The development of FINEVISION HP was a pivotal moment for ophthalmology, reshaping expectations for vision correction after cataract surgery,” said Dr. Damien Gatinel, developer and ophthalmologist. “FDA approval in the U.S. means even more patients will benefit from this breakthrough technology.”

"The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services.

"The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed, and veterinary products.' (Wikipedia)

Clinical and Market Significance

Created the category. FINEVISION HP was a breakthrough diffractive design creating the world’s first trifocal IOL, establishing an entirely new standard in cataract surgery.
Exceptional reliability. With more than a decade of real-world clinical results, millions of successful implantations and strong surgeon preference, FINEVISION HP remains the most trusted trifocal lens.
Unique design. Featuring BVI’s proprietary POD platform, FINEVISION HP utilizes CoPODize™ technology to harmonize light distribution and minimize visual disturbances, while its double C-loop haptic system ensures lasting stability and precise centration. (official website)

"FINEVISION HP redefined premium cataract surgery and continues to set the gold standard in premium IOL innovation,” said Shervin Korangy, president and CEO of BVI. “This FDA approval marks a pivotal step in expanding our IOL portfolio in the United States, supporting our mission to deliver best-in-class visual outcomes for patients globally.”

"“The development of FINEVISION HP was a pivotal moment for ophthalmology, reshaping expectations for vision correction after cataract surgery,” said Dr. Damien Gatinel, developer and ophthalmologist. “FDA approval in the U.S. means even more patients will benefit from this breakthrough technology.” (official website)

"BVI Medical has gained US Food and Drugs Administration (FDA) approval for FineVision HP, the world’s first trifocal intraocular lens (IOL) for cataract surgery, in an effort to expand coverage in the IOL market and more specifically the multifocal intraocular lens market," the Medical Device Network says.

"The IOL market was worth $4.6 billion worldwide in 2024 and is projected to reach $5.6 billion in 2034 with a compound annual growth rate (CAGR) of 2.1%. The multifocal IOL market was worth $820.5 million in 2024 and is estimated to reach $977.3 million in 2034 with a CAGR of 1.8%, according to GlobalData, a leading data and analytics company."

"The company touts FineVision HP as the world’s first trifocal IOL, bringing in a new era of premium IOL offerings. FineVision HP features a patented diffractive optic design, delivery balanced vision at far, intermediate and near distances.

"Christophe Pagnoulle, BVI’s R&D director, and Dr. Damien Gatinel, an ophthalmologist, brought FineVision HP to market. The company says its latest milestone reinforces its leadership in premium IOLs, expanding advanced vision solutions for U.S. patients," the Mass Device says.

"BVI Medical, a global leader in ophthalmic device innovation, announced that the U.S. Food and Drug Administration (FDA) has approved its FINEVISION HP trifocal intraocular lens (IOL). This milestone underscores BVI’s leadership in premium IOLs and expands access to advanced vision correction solutions for patients in the United States.

"The FINEVISION HP is the world’s first trifocal IOL, recognized globally for its patented diffractive optic design, which provides balanced vision at far, intermediate, and near distances," the Voice of Health Care says.

"Developed through the pioneering efforts of Christophe Pagnoulle, BVI R&D Director, and ophthalmologist Dr. Damien Gatinel, the lens has over 15 years of clinical success and millions of implantations worldwide, setting a benchmark for premium cataract surgery.

"BVI, one of the fastest growing surgical ophthalmic businesses in the world, is thrilled to announce the official launch of FINEVISION HP in Japan," the official website says.

"The FINEVISION HP hydrophobic and glistening free trifocal IOL represents a significant breakthrough in trifocal technology as the first trifocal platform to offer cataract patients high quality vision across all distances.

"Given substantial excitement and interest in the product, BVI Japan has already received orders for FINEVISION HP and will host the official launch event at the upcoming Japanese Society of Cataract and Refractive Surgeons (JSCRS) annual meeting in Sapporo, Japan on June 22 through June 24. Dr. Kazunori Miyata (Miyata Eye Hospital), Dr. Hisaharu Suzuki (Zengyo Suzuki Eye Clinic), and Dr. Yousai Mori (Miyata Eye Hospital) will be presenting the results of the clinical trial conducted in Japan."